Podcasts about Thermo Fisher Scientific

On Your World of Creativity, we explore how innovators, entrepreneurs, artists, scientists, and thought leaders transform ideas into impact.Today's guest has spent three decades helping some of the world's most sophisticated science and healthcare companies answer a deceptively simple question:How do you persuade people who pride themselves on not being persuaded?Hamid Ghanadan is the founder and CEO of LINUS, a commercial strategy consultancy serving life science and healthcare innovators. A former biochemist turned strategist, Hamid has guided organizations including Twist Bioscience, Thermo Fisher Scientific, and 10x Genomics through product launches, market development, and growth initiatives.His new book, Not Buying It: The Art of Selling to Scientists, Doctors, and Other Professional Skeptics, challenges conventional thinking by arguing that even the most technical buying decisions are ultimately driven by psychology, empathy, and human behavior—not just data.Hamid 's WebsiteHamid on YouTubeHamid LinkedIn: https://www.linkedin.com/in/hghanadan/Let's explore creativity, persuasion, science, and what it takes to influence skeptical minds.Guest BioHamid Ghanadan is the Founder and CEO of LINUS, a commercial strategy consultancy focused on life sciences, healthcare, diagnostics, medical devices, and biotechnology.Originally trained as a biochemist, Hamid became fascinated with a question that would shape his entire career:How do scientists make decisions?That curiosity led him from the laboratory into marketing, strategy, and behavioral psychology. Over the past 30 years, he has developed what he calls an Insights-Led Commercial Strategy, helping science and healthcare organizations better understand customer decision-making and create meaningful demand.His new book, Not Buying It, explores how technical professionals evaluate information, why traditional marketing often fails with scientific audiences, and how empathy becomes a competitive advantage in high-stakes commercial environments.1: From Biochemist to Behavioral StrategistHamid, one of the stories I found fascinating is that your career began in a biochemistry laboratory.You describe an early encounter watching a salesperson struggle to connect with scientists, which sparked a question that changed your professional trajectory: How do you sell to such a skeptical audience? What was it about that moment that stayed with you, and how did it eventually lead you from science into strategy?2: The Psychology Behind Technical DecisionsOne of the central themes of your book is that commercial strategy is fundamentally a game of psychology. That can sound counterintuitive in industries built on evidence, data, peer review, and rigorous analysis. Yet you argue that scientists, doctors, engineers, and other technical professionals are still human beings first. What do most companies misunderstand about how highly educated professionals actually make decisions? Why isn't more data necessarily more persuasive?3: The Soul of the BrandLet's apply my favorite framework—the Soul of the Brand. Thinking about LINUS:What is your focus?What work are you really doing?Who are you serving?What gives you credibility?What industry assumptions are you challenging?And what larger mission drives the organization?4: Persuasion, Creativity, and the Age of AIIn the book, you make an interesting observation. AI is making it easier than ever to create content, automate outreach, and scale communications. But you suggest that simply producing more content creates more noise—not more influence. As someone who studies persuasion and decision-making, what concerns you most about how organizations are currently using AI? What human skills become more valuable in an AI-enabled world?5: Unlocking Influence Through EmpathyOne of the ideas that really resonated with me is your belief that the key ingredient of an effective strategy is a unique insight into audience psychology—and that finding that insight requires empathy. For leaders, marketers, entrepreneurs, healthcare innovators, and creative professionals listening today: How can they become better observers of human behavior and uncover those insights that others miss?If you enjoyed today's episode, please subscribe, rate, and review the podcast.

July 2026 Sustainable Stock and ETF Picks. Includes articles on the top sustainable pharmaceutical companies, clean energy ETFs, and more! By Ron Robins, MBA Transcript & Links, Episode 169, July 31, 2026 Hello, Ron Robins here. Welcome to my podcast episode 169, published on July 31, 2026, titled "July 2026 Sustainable Stock and ETF Picks." Now, before I begin, I want to apologize if my voice at any time sounds a little rough! This podcast is presented by Investing for the Soul. Investingforthesoul.com is your go-to site for vital global, ethical, and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript and links to content, including stock symbols and bonus material, on this episode's podcast page at investingforthesoul.com/podcasts. Also, a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, and I don't receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal any investments I have in the investments mentioned herein. I have a terrific crop of 27 articles for you in this podcast! Note: Sometimes companies are covered more than once. Now with so many articles to potentially cover, I've chosen 4 to quote from. Titles and links to the other 23 can be found on the webpage for this podcast edition. ------------------------------------------------------------- 1) Top 10: Sustainable Pharmaceutical Companies from sustainabilitymag.com I'm beginning this podcast with an article that reviews an industry that is controversial for some ethical and sustainable investors. Nonetheless, the sponsor of this industry analysis needs to be considered. The title of the article is: Top 10: Sustainable Pharmaceutical Companies from sustainabilitymag.com. It's by David Weston. Here is some of his analysis. "Here we present the pharmaceutical companies leading in corporate responsibility, innovation and dedication to a healthier, increasingly sustainable future. 10. Boston Scientific (BSX) Founded: 1979 HQ: Marlborough, US Net Zero Target: 2050 In the short term, it aims to achieve a 46.2% absolute reduction in Scope 1 and 2 emissions by 2030 – compared to a 2019 baseline. By 2050, it wants to achieve a 90% absolute reduction. 9. UnitedHealth Group (UNH) Founded: 1974 HQ: Eden Prairie, US Net Zero Target: 2050 UnitedHealth Group is working to source 100% of its energy from renewable sources and reduce Scope 1 and 2 emissions by 60% by 2030. 8. Danaher (DHR) Founded:1969 HQ: Washington, DC, US Net Zero Target: 2050 Danaher's 2025 Scope 1 and 2 emissions were 30% lower than the 2021 baseline, with 70% of the electricity consumed in its operations drawn from renewable sources. 7. Elevance (ELV) Founded: 1944 HQ: Indianapolis, US Net Zero Target: 2030 Elevance Health… uses 100% renewable electricity, and encourages suppliers to adopt science-based targets… Its initiatives include energy and water efficiency, responsible waste management and low-carbon commuting. 6. Medtronic (MDT) Founded: 1949 HQ: Minneapolis, US Net Zero Target: 2045 Medtronic aims to have 75% of its suppliers backed by science-based targets by 2030… Medtronic also wants to reduce absolute Scope 1 and 2 GHG emissions 52% by FY30 from a 2020 base year. Top 5... 5. McKesson (MCK) Founded: 1833 HQ: Irving, US Net Zero Target: Reduce direct GHG emissions by 50% by 2032. It aims to reduce direct GHG emissions by 50% by 2032 from a 2020 base year. 4. Bayer (BAYN) Founded: 1863 HQ: Leverkusen, Germany Net Zero Target: Before 2050 By the end of 2029, it targets a 42% reduction in Scope 1 and 2 emissions from a 2019 baseline. Strategies include… transitioning to 100% renewable electricity. 3. CVS Health (CVS) Founded: 1963 HQ: Woonsocket, US Net Zero Target: 2050 In 2021, CVS Health emerged as a global leader by securing SBTi validation for its net zero targets… The company is targeting 50% renewable electricity by 2040. 2. Haleon (H6G.SG) Founded: 2022 HQ: Weybridge, UK Net Zero Target: 2040 Haleon uses 100% renewable electricity across its production facilities. 1. Thermo Fisher Scientific (TN8.F) Founded: 2006 HQ: Waltham, US Net Zero Target: 2050 Thermo Fisher Scientific… interim targets including a 50% reduction in greenhouse gas emissions from 2018 levels and 80% renewable energy use by 2030." End quotes. ------------------------------------------------------------- 2) Riding the Green Wave: Clean Energy ETFs Benefiting from etftrends.com Now the case for green energy is clearer than ever, and this article offers reasons for it and what investments to look at. It's titled Riding the Green Wave: Clean Energy ETFs Benefiting from etftrends.com. It's by Ryan Schloesser, and here are some quotes from his article. "Following a multi-year slump in clean energy ETF performance, geopolitical tensions sparking global energy security concerns and energy demand from AI data center projects have driven clean energy investment in 2026… (Starting with) Gains in (3) Global Clean Energy (ETFs) 1. iShares Global Clean Energy ETF (ICLN) tracks the performance of the S&P Global Clean Energy Index… (The) iShares Global Clean Energy ETF has climbed over 20%, and has received inflows of $507 million so far in 2026. 2. Fidelity Clean Energy ETF (FRNW) tracks the Fidelity Clean Energy Index, targeting global companies that derive at least 50% of their revenues from renewable energy. The fund has seen a return of 17.3% and inflows of $60 million this year.  3. Invesco Global Clean Energy ETF (PBD) follows the performance of the WilderHill New Energy Global Innovation Index… (The) Invesco Global Clean Energy ETF has climbed 19% and recorded inflows of $6.5 million in 2026.  Capturing the North American Energy Shift (are the following 4 funds) 1. Invesco WilderHill Clean Energy ETF (PBW) tracks the WilderHill Clean Energy Index… The fund has climbed 20.6% this year with outflows of -$305.2 million as surging Treasury yields and potential interest rate hikes pressure smaller-cap holdings.  2. First Trust NASDAQ Clean Edge Green Energy Index Fund (QCLN) tracks the NASDAQ Clean Edge Green Energy Index targeting North American companies across the green value chain… The fund has grown 27.2% this year and received inflows of $110 million.  3. ALPS Clean Energy ETF (ACES) and 4. (the) ALPS Electrification Infrastructure ETF (ELFY) both provide North American exposure to the clean energy sector. (The) ALPS Clean Energy ETF tracks the CIBC Atlas Clean Energy Index… Focusing more on the electrification infrastructure component of the clean energy transition, (the) ALPS Electrification Infrastructure ETF tracks the Ladenburg Thalmann Electrification Infrastructure Index, providing exposure to the companies physically supplying electricity and grid infrastructure. This year, the funds have returned 5.4% and 22.7%, with inflows of $12.8 million and $58.6 million, respectively.  (And 2) Pure Play (Funds with) Exposure to Solar and Wind 1. Invesco Solar ETF (TAN) offers concentrated exposure to a portfolio of companies involved in the global solar value chain by tracking the MAC Global Solar Energy Index. 2. First Trust Global Wind Energy ETF (FAN) tracks the ISE Clean Edge Global Wind Energy Index. (The) Invesco Solar ETF has returned 14.7% with inflows of $536.1 million in 2026, while (the) First Trust Global Wind Energy ETF has risen 21.8% and recorded inflows of $62.8 million over the same period." End quotes. ------------------------------------------------------------- 3) 3 AI Infrastructure Stocks That Could Double by 2027 from finance.yahoo.com Many ethical and sustainable investors are heavily invested in the AI sphere. So as an homage to them, I have this recent article titled 3 AI Infrastructure Stocks That Could Double by 2027 from finance.yahoo.com. It's by Will Healy at fool.com. Here's a bit of what he says in his article. "1. Nvidia (NVDA) trades at a P/E ratio of 31, which is actually less than the S&P 500 average of 32. This has occurred as Nvidia's revenue grew by 85% yearly in the first quarter of fiscal 2027 (ended April 26). When also considering the 211% profit increase for the same period, the earnings multiple would arguably appear low even if Nvidia's stock price were to double. 2. CoreWeave (CRWV) As one of the leading neocloud companies, CoreWeave has drawn increased attention. Amid the potential for massive stock gains, huge losses and rapidly rising debt levels have soured some investors on this company… CoreWeave has Nvidia as an investor and a partner. That gives the company capital and access to Nvidia's latest technology, giving CoreWeave a competitive advantage. 3. Meta Platforms (META) Facebook parent Meta Platforms is in the process of transitioning into more of an AI-oriented enterprise. The company pledged to spend between $125 billion and $145 billion in capital expenditures (capex), most of which will probably go to building more AI infrastructure… Indeed, the 26% forecasted revenue increase for 2026 is a slowdown from Q1. Nonetheless, that would put downward pressure on an already low P/E ratio if the stock price stayed the same. Moreover, if Meta's AI inspired more confidence, its current valuation indicates the stock price could double without making Meta an expensive stock." End quotes. ------------------------------------------------------------- 4) Top Wind Energy Stocks to Add to Your Portfolio for Solid Long-Term Returns -- from Zacks.com Lastly, I have this article covering a sector that most of you are concerned with. It's titled Top Wind Energy Stocks to Add to Your Portfolio for Solid Long-Term Returns -- from Zacks.com. It's by Avisekh Bhattacharjee. Here are some quotes from his article. "(Note that this is) an updated edition of the May 28, 2026 article. 1. NextEra Energy (NEE - Free Report) is a public utility holding company engaged in the generation, transmission, distribution and sale of electric energy. The Zacks Rank #2 (Buy) company's competitive energy business, NextEra Energy Resources LLC ('NEER'), is a leading generator of wind energy globally. 2. Duke Energy (DUK - Free Report) is a premier utility service provider offering efficient power and energy services. The Zacks Rank #2 company is currently focused on expanding its scale of operations, implementing modern technologies at its facilities as well as enhancing its renewable generation portfolio by investing heavily in infrastructure and expansion projects. 3. American Electric Power (AEP - Free Report) is a public utility holding company, which, through directly and indirectly owned subsidiaries, generates and transmits electricity. Wind forms a part of the company's broader strategy to diversify its generation portfolio and lower carbon emissions… The Zacks Rank #2 company is expanding its regulated renewable asset base. 4. Vestas Wind Systems (VWDRY - Free Report) is a renowned designer, manufacturer, installer and service provider for wind turbines across the globe. To capitalize on rising demand for renewable power, the company emphasizes wind capacity expansion, technological advancement and sustainable energy development… In June 2026, the Zacks Rank #2 company secured five new orders to deliver wind turbines in Germany." End quotes. ------------------------------------------------------------- 23 more articles from around the world with Sustainable Investment Picks for July 2026. 1. Title: This Solar Power Stock Still Has a Bright Future from barrons.com. By Avi Salzman. 2. Title: Solar Beats Coal for the First Time: 3 Dividend Stocks to Buy Now from fool.com. By Reuben Gregg Brewer. 3. Title: 3 Consumer Staples Stocks Riding The Fairtrade Spending Trend from simplywall.st. Reviewed by Sasha Jovanovic. 4. Title: 1 Nvidia-Backed AI Infrastructure Stock to Buy Hand Over Fist Right Now from fool.com. By Dave Kovaleski. 5. Title: Top 10: Wind Power Companies from energydigital.com. By James Darley. 6. Title: This AI Infrastructure Company Has a $638 Billion Backlog and Is Trading Near an 18-Month Low from fool.com. By Matt Frankel, CFP®. 7. Title: 3 Green Investment Stocks Backed By Copper, Biofuels And Solar Demand from simplywall.st. Reviewed by Sasha Jovanovic. 8. Title: Forget Nvidia: This Infrastructure Upstart Is The Real Backdoor AI Winner from fool.com. By Leo Sun. 9. Title: 3 Stocks to Buy on the AI Infrastructure Sell-Off from fool.com. By Geoffrey Seiler. 10. Title: This ESG ETF Owns Google and Intel but Won't Touch Meta, and It's Up 22% in a Year from finance.yahoo.com. By Michael Williams at 24/7 Wall St. Continuing 12. Title: 3 Alternative Energy Stocks Investors Are Watching After The Oil Shock from simplywall.st/. By Sasha Jovanovic. 13. Title: ENVX Stock Soars at Yahoo: Is This the Next Big Environmental Investment?! From catalogo.cpal.edu.pe/. By CPAL. 14. Title: Buy 3 High-Flying Alternative Energy Stocks to Tap AI Data Center Boom from Zacks.com. By Nalak Das. 15. Title: 1 Growth Stock That's Pulled Back 39% and Looks Worth Buying Aggressively Right Now from theglobeandmail.com. By Sneha Nahata at fool.ca. 16. Title: 3 Green Energy Stocks to Buy in July from finance.yahoo.com. By Joel South. 17. Title: 2 AI Infrastructure Stocks That Could Outperform NVIDIA from zacks.com. By Tirthankar Chakraborty. 18. Title: ESG Investors: Why This Dividend ETF Is a Top Pick from ca.finance.yahoo.com. By Baystreet.ca. 19. Title: AI Infrastructure Will Mint More Millionaires Over the Next Decade: 3 Stocks to Buy Right Now from fool.com. By Leo Sun. 20. Title: AI Stocks Investment Strategy 2026: Top Picks & Market Analysis from intellectia.ai. By Jason Huang. 21. Title: 3 Climate Finance Stocks Linked To The World Bank Green Funding Push from simplywall.st. Reviewed by Sasha Jovanovic. 22. Title: BE vs. PLUG: Which Alternative Energy Stock Looks More Attractive? From zacks.com. By Tanuka De 23. Title: 4 High-Growth AI Infrastructure Stocks to Buy for Long-Term Gains from zacks.com. By Anirudha Bhagat. ------------------------------------------------------------- Ending Comment These are my top news stories with their stock and fund tips for this podcast, "July 2026 Sustainable Stock and ETF Picks." Please click the like and subscribe buttons wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And do click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope and prosperity in these tumultuous times! Contact me if you have any questions. Thank you for listening. Again, I want to apologize for my voice sounding, at times, a little rough! My next podcast will be on August 28th. See you then. Bye for now. © 2025 Ron Robins, Investing for the Soul

Molecular biology is more than a set of techniques. It is a toolkit for asking better questions. In this special crossover episode of Speaking of Mol Bio, Steve Lewis welcomes Jordan Ruggieri, Senior Marketing Manager at Thermo Fisher Scientific and co-host of the Absolute Gene-ius podcast. Jordan shares how Absolute Gene-ius began with a focus on digital PCR and evolved into a broader celebration of molecular genetics, genomics, and the scientists using diverse tools across multiple research areas. From endpoint PCR and qPCR to digital PCR, sequencing, sample prep, and downstream analysis, the conversation highlights how different technologies work together to help researchers move from sample to answer. Jordan also reflects on memorable podcast stories, including Antarctic microbial research, transplant science, lab mishaps, and the ways PCR-enabled discoveries can have real-world human impact. The episode also explores themes that run through many scientific careers: curiosity, grit, mentorship, failure, and openness to unexpected opportunities. Jordan shares his own path from aspiring dentist to R&D scientist, marketer, and podcast host, while offering early-career scientists practical advice: stay open, keep learning, and make time for hobbies and life outside the lab. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success.For today's episode, David Brühlmann is joined by David Hardy, a leader at Thermo Fisher Scientific. With years spent guiding automation and digital lab transformation projects around the globe, David's perspective is equal parts pragmatic and visionary. He's watched automation go from pilot to scale, advised on the messy realities of lab data, and seen firsthand what separates science fiction from science fact in fully connected labs.In this episode:Bottlenecks in lab automation, especially the challenge of scaling data volume and adapting processes (02:26)Differences between machine learning (ML) and generative AI in lab contexts, and why ML remains central to value extraction (04:17)The key requirements for successful AI adoption: quality data, robust data checking processes, and a cyclical approach to model training (05:25)The vision for an AI-enabled, fully connected lab and the role of predictive maintenance and data quality checks (07:24)Data governance strategies: balancing access and security, and the case for data democratization within organizations (09:32)How data standardization paves the way for better AI and smoother connectivity (11:25)The necessity of treating digital transformation as an ongoing journey, not a one-time project (12:15)Smart insight: digital transformation is not a one-off project but a long-term journey. The most important takeaway for any scientist or leader? Prioritize good quality, standardized data; invest in the foundational work; and foster a culture of collaboration and learning.The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony CatacchioEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val - Part 1Connect with David Hardy: LinkedIn: www.linkedin.com/in/david-hardy-46331823 Thermo Fisher Scientific website: www.thermofisher.comNext: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurdle.David Hardy, a leading market and innovation strategist at Thermo Fisher Scientific with 25 years of experience at the intersection of data, automation, and laboratory science, is helping organizations bridge the gap between data chaos and actionable insight.Topics discussed:David Hardy's early experiences managing NMR data at AstraZeneca and the origins of his interest in data management (03:46)Lessons from retail analytics and returning to scientific data challenges (05:21)Identifying the persistent problem of data connectivity in labs, despite growing data volumes and new technologies (06:40)The most common pushbacks to digital solutions: long-term commitment and culture change (07:38)What mindsets and leadership approaches support successful digital transformation (08:43)Recognizing fragmentation and spotting “hidden” data silos in biotech labs (10:06)Where data fragmentation hurts the most—especially for cross-disciplinary questions and CMC reporting (11:06)Build vs. buy: deciding whether to create in-house digital tools or work with external vendors (13:50)The importance of adaptable systems and preparing for inevitable change in biotech data management (14:43)Smart insight: True digital transformation is not a project, but a process—a way of working that requires vision, patience, and continual adaptation. The labs that break down data silos and connect their digital resources are better positioned to unlock the full promise of biotech: faster discoveries, more robust compliance, and therapies delivered to patients without unnecessary delay.The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony CatacchioEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValConnect with David HardyLinkedIn: www.linkedin.com/in/david-hardy-46331823Thermo Fisher Scientific website: www.thermofisher.comNext step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Great science doesn't always translate into a scalable product, and that gap can stall even the most promising innovations. In this Mol Bio Minutes episode, Steve Lewis explores a common challenge in biotech: moving from a validated assay or prototype to a commercially viable product. While scientific teams often achieve strong early results, scaling requires coordination across design, engineering, materials, and manufacturing, which typically involves multiple vendors. This fragmented process introduces delays, misalignment, and risk. The episode highlights how physical product design, especially for consumables like microfluidic cartridges or custom plastics, can ultimately determine whether a solution reaches the market. By integrating design, prototyping, and manufacturing under one roof, Thermo Fisher Scientific's Plastics Prototyping Services aim to streamline this transition. Early consideration of materials, manufacturability, and reagent compatibility enables faster iteration and more efficient scale-up, particularly for startups navigating growth stages. Ultimately, the message is clear: if your biology works but your product doesn't scale, the problem is solvable. With the right integrated approach, innovation doesn't have to stall, it can move efficiently from idea to impact. Helpful resources and links: Learn more about Thermo Fisher Plastics Prototyping Services Access information about reagents and raw materials for use in your product(s) Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Ce vendredi x mois année, Liste INVITES et FONCTiON, se sont penchés sur les titres (....à lister... ), dans On achète ou on vend ? dans l'émission C'est Votre Argent présentée par Marc Fiorentino. C'est Votre Argent est à voir ou écouter le vendredi sur B

This episode is part of the Engineering Matters Awards series, recognising individuals and organisations making an outstanding contribution to the engineering profession and wider society. Engineering is often judged by technical achievements: better products, more efficient processes, and breakthrough innovations. But some of the industry's most meaningful contributions happen beyond the core aims of the work itself. The role of engineers in society is to solve problems and create a more liveable world. Through the development of a project or a product an engineer may have the opportunity to bring about a wider community benefit, beyond solving the primary problem. It is those choices that this award recognises. In this Engineering Matters Awards episode, we celebrate two Bronze-level winners in the Community Champion category: Dremere Woods of Honda Development and Manufacturing of America, and Gaurav Mittal of Thermo Fisher Scientific. Join us as we explore why engineering excellence is not only about solving problems, but also about improving lives. Guests: Gaurav Mittal, Data Science Manager, Thermo Fisher Scientific Dremere Woods, Supplier Quality Engineer, Honda Development and ManufacturingThe post #368 Community Champion – Engineering Matters Awards first appeared on Engineering Matters.

Most professionals believe promotions are earned through performance alone.In reality, career progression is influenced by a combination of performance, potential, visibility, relationships, and leadership capability.In this episode of Espresso with Lewis, Lewis Maleh sits down with Kelly McGinnis, President of Business Operations at Thermo Fisher Scientific, to explore what separates those who continue to advance from those who remain stuck despite delivering strong results.They discuss:• Why performance alone doesn't guarantee promotion• What leaders look for when identifying future executives• The importance of peer relationships and internal networks• How to demonstrate leadership before you have the title• Career ownership and professional growth• Workplace complacency and staying relevant• AI adoption and the future of work• The widening gap between professionals who adapt and those who don'tA practical conversation on leadership, career progression, talent development, and what it really takes to succeed in today's workplace.----Connect with Kelly: https://www.linkedin.com/in/kellyamcginnisConnect with me: https://www.linkedin.com/in/lmalehLearn more: https://bentleylewis.com

19. mai 2026 Thermo Fisher Scientific har 130 000 ansatte og omsetter for 45 milliarder dollar – og noe av det mest spennende som skjer i selskapet globalt, skjer her på Campus Radiumhospitalet i Oslo. I dag har vi med oss Karoline Schjetne, forskningssjef, og Tuva Holt Hereng, senior manager innen celleterapi R&D. Vi snakker om en ny nanopartikkelplattform som lanseres i 2026, om celleterapi som fremtidens kreftbehandling, og om en ny bioreaktor som kommer i høst. Og om hvorfor Norge – mot alle odds – spiller en sentral rolle i et av verdens største bioteknologiselskaper. Neste uke møter vi Alfred Fidjestøl, som nettopp har skrevet Radiumhospitalets historie. Ikke gå glipp av det.

"At Kindeva, we want to be viewed as a fully Annex 1 compliant facility and partner that can pivot when needed and supply uninterrupted to the patients that need it." Tommy Shornak, Senior Vice President of Sterile Injectables at Kindeva, brings nearly 20 years of sterile manufacturing operations experience from organizations including AMRI, Thermo Fisher Scientific, and Gilead Sciences. Since joining Kindeva in 2025, Tommy has been at the center of the company's investment strategy.In the latest PharmaSource podcast, Tommy explains why Kindeva's approach to sterile injectable CDMO services, anchored by a $200 million facility investment, a no-single-source supply policy, and a shift toward flexible commercial models, is designed to position the company as a one-stop partner for drug sponsors navigating an increasingly complex outsourcing landscape.Read more.

Process Analytical Technology (PAT) has evolved from a niche troubleshooting tool into a strategic necessity—but most companies still implement it too late.  Dr. Stanislav Kazakov from Thermo Fisher Scientific reveals why starting PAT early can mean the difference between scaling success and costly manufacturing failures.Discover how real-time process insights, AI-driven chemometrics, and strategic implementation are reshaping quality control from lab to commercial scale across pharma and biotech.----------------------This episode is supported by Thermo Fisher Scientific. partners across the drug lifecycle to accelerate discovery, scale manufacturing, and ensure compliant release. Our analytical and process technologies support pharmaceutical and biotech teams from research and formulation through commercial manufacturing and quality control. With integrated instrumentation, workflow solutions, and expert service, we help protect yield, ensure data integrity, and deliver therapies to patients with confidence.----------------------Visit ⁠www.qualistery.com⁠ for live free webinars for GxP professionals, to stay on top of the latest industry trends.

6. mai 2026 I denne episoden møter Elisabeth Carl Christian Gilhuus-Moe, tidligere leder av Dynal Biotech. Sammen tar de en reise gjennom en av de mest bemerkelsesverdige historiene i norsk helsenæring – fra John Ugelstads gjennombrudd på 1970-tallet til et globalt selskap solgt for 2,5 milliarder kroner. Vi hører om mannen bak oppdagelsen: hvem John Ugelstad var, og hvordan han klarte noe NASA mente var umulig på jorden – å produsere helt identiske, monodisperse kuler. Carl Christian forteller om den lange og krevende veien fra laboratorium til marked, om etableringen av Dynal i 1986, og om samarbeidet med Radiumhospitalet som var avgjørende for å utvikle kulene til medisinsk bruk. Episoden byr også på refleksjoner rundt arven etter Dynal – kulene som i dag brukes i 50 diagnostiske tester per sekund, verden over, døgnet rundt – og hva Norge kan lære av denne historien når vi skal bygge morgendagens helsenæringsselskaper.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Steve Favaloro, Chairman and CEO of Genezen. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Steve, covering: His deep passion for operations, and how early lessons in hard work and customer service shaped his leadership Learning from Mark Bamforth and the entrepreneurial journey at Brammer Bio, culminating in a $1.7bn exit to Thermo Fisher Why gaining exposure to every seat at the table was critical in preparing him for the CEO role Building Genezen with a focus on strong values, hiring the right people and investing in differentiated capabilities How the cell and gene therapy market has evolved over the past decade, and why he remains optimistic about the future of curative medicines Why things inevitably go sideways in innovative drug development, and the importance of being prepared to navigate it Steve Favaloro is an experienced biotech executive, board member, and investor. He is currently Chairman and CEO of Genezen, a best-in-class gene and cell therapy CDMO with specialized expertise in viral vector manufacturing. Steve joined Genezen in 2023 and has built up a team of almost 300 employees, supporting gene and cell therapy innovators from early-stage, growth-oriented biotechs to established industry leaders. He is an executive advisor at Ampersand Capital Partners, a leading healthcare investor, and serves on the board of Biologos. He also serves on the board of advisors of Life Science Cares Boston. Prior to Genezen, Steve was CFO at Arbor Biotech, a next-generation gene editing therapeutic company. Steve also served as CFO at Arranta Bio, a leading CDMO for mRNA, from its founding in 2019 to its successful exit to Recipharm in February 2022.  Prior to this, Steve was a finance leader and ultimately CFO at Brammer Bio, where he oversaw a period of rapid expansion and capital deployment from 2016 to 2019 – leading up to its successful sale to Thermo Fisher Scientific in May 2019 for $1.7B. Before joining Brammer, Steve held finance roles of increasing responsibility at MilliporeSigma, Merck KGaA, and Bruker Corporation. Steve received his MBA and Master of Science from the Carroll School of Management at Boston College. Steve also received his Bachelor of Arts degree in Economics from Boston College.   Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a fascinating array of industry shifts and scientific breakthroughs that are shaping the future of medicine and patient care. Sun Pharma's acquisition of Organon for $11.75 billion is making waves as it marks a significant expansion for the Indian pharmaceutical giant into international markets. This deal not only amplifies Sun Pharma's footprint but also integrates Organon's strong focus on women's health and biosimilars into its portfolio. It's a strategic move that underscores the increasing trend of cross-border mergers as companies seek to diversify and enhance their global presence. As the largest-ever overseas acquisition by an Indian firm, this transaction is emblematic of the growing importance of global consolidation in the pharma industry. Meanwhile, Astellas Pharma faces a mixed fiscal outlook with its prostate cancer drug Xtandi. While Xtandi experienced a modest sales increase in 2025, a projected decline for 2026 has prompted Astellas to pivot towards developing new medicines. This highlights the critical dependence on innovation within the industry to sustain growth, especially as competition intensifies. In the realm of ATTR amyloidosis treatments, Pfizer has reached a settlement with two generic manufacturers over its drug Vyndamax. This resolution is crucial in stabilizing the market amidst rising generic competition, which can significantly influence pricing and market dynamics. Such settlements are an integral part of maintaining competitive positioning in crowded therapeutic spaces. Ligand Pharmaceuticals' strategic purchase of XOMA for $739 million signals a broader trend of consolidation among biotech royalty aggregators. This acquisition aligns with Ligand's strategy to augment its portfolio through mergers and acquisitions—a recurring theme as biotech companies strive to streamline operations and expand their competitive edge. The competition within the oral GLP-1 market is intensifying, particularly with Eli Lilly's delayed launch of Foundayo inadvertently benefiting Novo Nordisk's market position. This rivalry underscores the fierce race to dominate the lucrative obesity management sector, highlighting how pivotal timing can be in gaining market share. The FDA's recent allocation of national priority vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics marks a significant regulatory shift towards embracing psychedelic therapies. These vouchers could expedite development timelines, thereby accelerating patient access to novel treatments that have traditionally been underexplored. Thermo Fisher Scientific's robust start to 2026 showcases how strategic acquisitions like that of Clario can drive growth. This reflects broader industry trends where biopharma companies leverage technological advancements to enhance capabilities in clinical trial support and data management. In gene editing news, Intellia Therapeutics is advancing towards FDA approval for its in vivo CRISPR therapy following successful Phase 3 trials. This progress heralds a new era for gene editing technologies in treating genetic disorders, underscoring their potential to revolutionize therapeutic approaches. Eli Lilly continues its aggressive acquisition strategy by purchasing Ajax Therapeutics for $2.3 billion. This acquisition focuses on next-generation JAK inhibitors for myelofibrosis, aligning with Lilly's broader goal to diversify its pipeline and maintain its leadership in innovative therapeutics. Recent studies have also shed light on how an endoscopic procedure used in Europe can aid patients on Eli Lilly's tirzepatide in maintaining weight loss post-treatment. This finding could significantly impact long-term obesity management strategies, offering new insights into sustainaSupport the show

Sustainability in clinical research does not have to be overwhelming. In this episode of SCRS Talks, Lauren Stockwell is joined by Paula Underhill of PPD part of Thermo Fisher Scientific and Clare Grace, CEO of EMS Healthcare and the 2025 Excellence in Site Sustainability Award recipient. Claire walks through the concrete changes EMS implemented across its mobile unit model, including solar integration, employee-led sustainability committees, and science-based targets aligned with the Paris Agreement. Paula adds context on what the judging panel found compelling and how CROs can serve as true sustainability partners rather than just cheerleaders. Whether your site is just getting started or well on its way, this conversation will leave you with a clear message: start small, start now.

In this Mol Bio Minutes mini-episode of Speaking of Mol Bio, Dr. Andrea Hunger walks listeners through the practical differences between three core PCR approaches: endpoint PCR, quantitative PCR (qPCR), and digital PCR. Drawing on her experience in both academic research and industry, she explains how each technique provides different types of information and why choosing the right one depends on the biological question being asked.  Endpoint PCR is the simplest method and is ideal for basic presence-or-absence questions such as confirming cloning success or genotyping samples. While fast and accessible, it does not provide quantitative information. For experiments requiring measurement of gene expression levels or comparisons between samples, qPCR offers a powerful solution by monitoring amplification in real time and using Ct values and standard curves to estimate starting concentrations. Hunger then discusses digital PCR, a newer technology that partitions samples into many micro-reactions to enable highly precise, absolute quantification of nucleic acids. Because it counts positive and negative partitions directly, digital PCR is especially valuable for detecting rare mutations, low-abundance targets, and applications like liquid biopsy analysis. Ultimately, she emphasizes that these PCR approaches are complementary tools, and the best experimental strategy is to choose the method that provides the level of information required for the next step in a research workflow. Helpful resource links mentioned in this episode:  Access educational eBook covering all three types of PCR and their use in gene expression analysis.  Watch a video on when to choose digital vs. real-time PCR.  Use the PCR primer design tool from Thermo Fisher.  Access Harvard's PrimerBank, a public resource of PCR primers. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

In this episode of From Lab to Launch, we're joined by Noreen Hong, VP and General Manager of Thermo Fisher Scientific's Growth Protection and Separation business. Noreen shares insights from her extensive career, including what has kept her at Thermo Fisher for so many years and how a strong mission-driven culture and commitment to people development can shape lasting leadership. She discusses the importance of creating more inclusive hiring practices in STEM, encouraging women and underrepresented groups to pursue opportunities even when they don't meet every requirement. Noreen also reflects on the value of trusting your instincts and taking smart risks to accelerate career growth. The conversation explores how labs can operate more sustainably through equipment upgrades and better data traceability, and looks ahead to the impact of AI and connected technologies in transforming modern laboratories. Qualio website:https://www.qualio.com/Previous episodes:https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Alessandro Maselli, President and Chief Executive Officer at Catalent and Franco Negron is the Chief Executive Officer at Simtra BioPharma Solutions.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his esteemed guests during a live fireside chat at the DCAT Morgan Stanley CDMO CEO Dinner.   Alessandro Maselli is the President and Chief Executive Officer of Catalent, having assumed the CEO role in July 2022 after serving as the company's President and Chief Operating Officer since February 2019.  He has been with Catalent since 2010 and has played a central role in shaping the company into one of the world's leading contract development and manufacturing organizations serving pharmaceutical, biotechnology, and consumer health customers globally.   Alessandro joined Catalent as Director of Operations at the company's pharmaceutical, nutrition, and cosmetics facility in Italy. Over the course of more than a decade, he progressed through a series of increasingly senior leadership roles, including General Manager of the Zydis® operations in Swindon, U.K., Vice President of Operations for Europe within the Drug Delivery Solutions business, and Senior Vice President of Global Operations. In these roles, he oversaw multi-site global manufacturing networks, large-scale capacity expansions, and complex technology platforms across oral solid dose, biologics, and advanced delivery modalities.   As Chief Executive Officer, Alessandro led Catalent through the COVID-19 pandemic, during which the company played a critical role in the global response by supporting vaccine and therapeutic manufacturing at unprecedented scale. More recently, he has overseen Catalent's transition to private ownership following its $16.5 billion acquisition by Novo Holdings, positioning the company for long-term investment and growth as a privately held global CDMO.   Prior to joining Catalent, Mr. Maselli held a range of operational and business leadership roles at ABB Group, Alstom, and SGS, gaining extensive experience in industrial automation, engineering, and large-scale manufacturing operations. He began his career as an automation systems engineer in the food industry. In addition to his executive role, Alessandro serves on the Board of Directors of Graphic Packaging Holding Company, to which he was appointed in May 2025. He holds bachelor's and master's degrees in electronic engineering from the University of Rome and is a native of Italy.   Franco Negron is the Chief Executive Officer of Simtra BioPharma Solutions, a leading sterile injectable contract development and manufacturing organization formed following the divestiture of Baxter International's BioPharma Solutions business. He was appointed CEO in 2023 by Advent International and Warburg Pincus to lead the business as an independent, private-equity-backed CDMO focused on clinical-to-commercial parenteral manufacturing. Franco is an industry veteran with nearly 30 years of pharmaceutical and biopharmaceutical experience, bringing deep expertise across sterile manufacturing, commercial operations, and global supply chain leadership. Prior to joining Simtra, he served as Chief Executive Officer of ApiJect Systems America, a medical technology company focused on advanced drug-delivery and injection systems. Earlier in his career, he held senior executive roles at Thermo Fisher Scientific, where he served as President of Commercial Operations, and at Patheon Pharmaceuticals, where he was President of Development and Commercial Operations, North America, playing a key role in scaling Patheon's CDMO platform prior to its $7.2 billion acquisition by Thermo Fisher in 2017.   Franco has also held leadership positions at several major pharmaceutical companies, including Vice President of Manufacturing and Supply at Valeant Pharmaceuticals, Global Vice President within Novartis' Consumer Health division, and Site General Manager at McNeil Consumer Healthcare.   Across these roles, he developed a reputation for operational excellence, customer-centric leadership, and the ability to lead complex manufacturing organizations through periods of transformation and growth. As CEO of Simtra, Franco is leading the company through its next phase of expansion, focused on strengthening its sterile fill-finish capabilities, advancing technical differentiation, and investing in capacity to support increasing demand for injectable biologics, vaccines, and complex parenteral products   Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

While 69% of American employees consider work-life balance "very important," only approximately 53–54% of chairpersons and CEOs report the same, often emphasizing "harmony" or "integration" rather than traditional work-life balance, according to Fortune Magazine. Prioritizing Balance: Job Selection: Work-life balance is a core consideration for 73% of employees when evaluating new job opportunities. (Global Banking and Finance Review) As CFO and President at Thermo Fisher Scientific, Kelly McGinnis exemplifies a hands-on approach to leadership that aligns with contemporary workplace priorities. Under her direction, innovative global digital initiatives generated over $1 billion in new revenue through bold subscription models, driving impressive annual growth of 15% by blending strategic acumen with emotional intelligence. Kelly has established a reputation for cultivating organizational cultures centered on trust, ownership, and mentorship—key drivers for creativity and performance. She actively challenges outdated paradigms of success by promoting confident leadership, work-life balance, and clear communication within corporate environments. Her perspectives on strategic decision-making and empowering emerging leaders, including millennials and Gen Z, are widely recognized. With extensive experience leading organizations to outperform market benchmarks, Kelly draws on disciplined growth strategies and people-centric cultures. Having worked across both Fortune 50 companies and agile startups, she understands how to build scalable, sustainable businesses. Her consistent focus involves assembling high-performing teams, creating frictionless systems, and aligning talent, partnerships, and commercial objectives with impactful outcomes. This approach has enabled organizations under her leadership to achieve more than 10% profitable growth annually, far surpassing standard industry rates. Kelly's efforts extend beyond margin improvement; she emphasizes the importance of reshaping a company's financial and operational foundations, clarifying decision-making processes, instilling accountability, and enabling cross-functional teams to translate strategy into effective execution—factors essential for lasting performance. In an environment characterized by uncertainty and short-term thinking, she advocates for leadership grounded in clarity and intentionality. Her five-rule leadership model fosters cultures where excellence is a collective standard. Recognized for converting potential into tangible enterprise value, Kelly believes that with the right mindset and system, any team can deliver exceptional results, and organizations of all sizes can realize their full potential. For more information: https://leadwithkelly.substack.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

On episode 288 of EHS On Tap, Lidija Raičević, VP of Global Commercial Operations, Chromatography and Mass Spectrometry, Thermo Fisher Scientific, talks about how PFAS is reshaping environmental and food testing lab operations.

What does it really take to build a sustainable biotech ecosystem outside of traditional hubs like Boston and San Francisco? In this episode, host Elaine Hamm, PhD, is joined by Christin Godale, PhD, Executive Director of LifeSciKY, to explore how regional innovation communities can grow from the ground up. Christin shares how LifeSciKY is helping entrepreneurs access lab space, shared equipment, mentorship, and community support. The conversation dives into the realities of building biotech infrastructure in emerging regions, and why success comes from leaning into local strengths, building partnerships, and creating opportunities for founders to succeed where they are. In this episode, you'll learn: Why successful biotech ecosystems rely on strong partnerships between government, industry, and academia. How regions outside traditional biotech hubs can build sustainable innovation communities by leveraging their unique strengths. What incubators and shared lab spaces must provide beyond real estate to truly support founders and early-stage companies. Tune in to learn how collaborative communities and intentional partnerships can transform regional innovation ecosystems and create new opportunities for biotech entrepreneurship. Links: Connect with Christin Godale, PhD, and learn about LifeSciKY. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine, as well as Cadenza Bio. Learn more about Thermo Fisher Scientific, Project Medtech, and SmartHealth Catalyzer. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

In this episode, we examine Thermo Fisher Scientific as a case study in modern biotech infrastructure and crisis response capability. The discussion explores the company's reach across laboratory tools, genetic data technologies, distribution networks, clinical execution, and pharmaceutical manufacturing, along with documented pandemic-era participation and expansion through acquisition. The episode also considers ethical concerns surrounding biological data technologies and surveillance applications, focusing on observable structure and incentives rather than speculation.These developments are viewed through a spiritual lens, asking how believers should respond to increasingly complex institutional systems intersecting with identity, commerce, and governance. The closing segment incorporates reflections from Pastor Chuck Baldwin's February 8, 2026 sermon, “Evangelicals' Divine Litmus Test,” connecting themes of discernment and spiritual allegiance with the investigative discussion.Email: thefacthunter@mail.comEvangelicals' Divine Litmus Test - 2/8/26 By Pastor Chuck Baldwin https://youtu.be/bgNLeTTXHC0?si=UTbHmjhRO6rCqzEb Give to Liberty Fellowship https://libertyfellowshipmt.com/Donate.aspxChuck Baldwin's Website: https://chuckbaldwinlive.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of insightful updates that highlight the dynamic and rapidly evolving nature of these sectors, driven by scientific advancements, regulatory shifts, and strategic industry maneuvers.Starting with Merck, which is strategically planning for a post-Keytruda era, projecting over $70 billion in annual opportunities over the next decade. With Keytruda's patent expiration looming in 2028, Merck is actively expanding its portfolio through acquisitions and partnerships, focusing on oncology and immunology. These areas have been significantly impacted by Keytruda's success, and Merck's proactive approach aims to sustain growth and innovation beyond its current flagship product. During their 2025 full-year earnings call, CEO Robert Davis emphasized their expansive pipeline, highlighting recent strategic deals as pivotal to Merck's robust pipeline—the broadest it has been in years—signaling long-term growth through diversified therapeutic areas and innovative drug candidates.The U.S. Food and Drug Administration (FDA) is making waves with its regulatory approach to CAR-T cell therapies for autoimmune diseases. This shift reflects an increasing recognition of the potential these therapies hold for transforming treatment paradigms for conditions like lupus and multiple sclerosis. By offering a more flexible regulatory framework, the FDA is encouraging innovation while maintaining a focus on patient safety.In other regulatory news, AstraZeneca faces a setback with the FDA's rejection of its subcutaneous version of Saphnelo for lupus. The decision underscores the challenges associated with developing more patient-friendly administration methods for biologics. However, AstraZeneca remains optimistic about achieving a quick turnaround in the approval process, which could enhance patient adherence by offering a self-administered alternative to intravenous infusions.Sanofi finds itself in the spotlight after CEO Paul Hudson was sanctioned by the UK's Prescription Medicines Code of Practice Authority for making overly ambitious claims about Pfizer's RSV vaccine. This incident illustrates the competitive nature of vaccine procurement and underscores the importance of accurate communication by pharmaceutical leaders.In Massachusetts, Thermo Fisher Scientific is reducing its workforce with the closure of its Franklin site, impacting around 200 employees. This move is part of broader strategic realignments within the industry aimed at optimizing operations and focusing resources on high-growth areas.Acadia Pharmaceuticals faces potential rejection by the European Union for its drug trofinetide intended for Rett syndrome. This highlights ongoing challenges in gaining approval for treatments targeting rare diseases, despite their significant unmet needs.Meanwhile, GSK plans to lay off up to 350 R&D workers across the U.S. and UK as part of efforts to streamline operations and focus on core therapeutic areas. Such layoffs reflect broader industry trends toward consolidation and efficiency amid rising R&D costs.On a more promising note, Pfizer's GLP-1 receptor agonist has demonstrated significant results in a Phase 2b trial for weight loss, validating their substantial investment in this area. The drug's potential to offer competitive weight loss results with monthly dosing positions it as a strong contender in the obesity treatment market. Additionally, Pfizer continues to accelerate its efforts in obesity treatment with promising mid-stage trial results for PF-3944, showing up to a 12.3% weight loss at 28 weeks. This suggests Pfizer is keen on expanding its presence in obesity management through strategic clinical development as competition within this therapeutic area intensifies.The U.S. Department of Health and HumanSupport the show

Send us a textThe NexusXp: The Connected Lab pavilion returns to SLAS2026 (Feb. 7-11), with an even sharper focus on integrative automation, seamlessly connecting devices, platforms and people to advance scientific workflows. In this episode, we speak with each participating NexusXp Integration Showcase sponsor to preview each company's innovative demonstration in the pavilion. Designed to spark collaboration between vendors and researchers, NexusXp highlights real-world lab automation scenarios that blend hardware, software and human ingenuity. See the timestamps for each course discussion below:00:00 — Ginkgo Bioworks (Jason Kelly, PhD)09:58 — Hamilton (Del Ray Jackson, PhD)17:15 — Thermo Fisher Scientific (Hansjoerg Haas, PhD)26:14 — Greiner Bio-One (Glauco Souza, PhD)Don't wait—Register for SLAS2026 International Conference & Exhibition today!Stay connected with SLAS:www.slas.org | Facebook | X | LinkedIn | Instagram | YouTubeAbout SLASSLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building. SLAS2026 International Conference & Exhibition February 7-11, 2026 Boston, MA SLAS Europe 2026 Conference and Exhibition 19-21 May 2026 Vienna, Austria View the full events calendar

We're back and better than ever. Season 4 of Absolute Gene-ius is officially here, and this teaser gives you a front-row seat to what's coming. From scientific puns to sneak peeks of the upcoming guest lineup, co-hosts Jordan Ruggieri and new addition Lisa Crawford set the tone for another season of engaging, educational, and entertaining molecular biology content.This season, the show expands its scope beyond digital PCR to include real-time PCR and other tools that are working together to move research forward in fields like oncology, agriculture, behavioral psychiatry, and more. Lisa brings a non-scientist's view to the show along with a deep passion for translating complex science into compelling stories. Whether it's microvesicles, stem cells, or high-containment biosafety labs, the upcoming episodes promise to be both technically informative and very human.And in classic Absolute Gene-ius fashion, we keep it fun. From how guests got into science, to what thy love most about it, and lab fail stories, the Career Corner returns with fresh energy and laughs. Expect bad puns, big discoveries, and the beautiful chaos of real-world research. Visit the Absolute Gene-ius page to learn more about the guests, the hosts, and the science we explore. Discover the Applied Biosystems QuantStudio Digital and Real-Time PCR Systems powering real-world research across neuroscience, oncology, agriculture, and more.

In this episode of From Lab To Launch, Meg is joined by Dr. Les Enterline, Senior VP and Global Head of Functional Service Partnerships at PPD, part of Thermo Fisher Scientific.With decades of experience across clinical research, Les is helping redefine how biopharma companies structure and scale their development teams through what's known as the FSP model: a flexible outsourcing approach that's gaining traction as sponsors face increasing pressure to deliver trials faster, more efficiently, and with more adaptive designs.As clinical complexity grows and internal teams get stretched thin, FSPs are helping organizations scale specialized expertise while maintaining oversight, quality, and operational control. Under Les' leadership, PPD has become one of the industry leaders in offering hybrid and fit-for-purpose models that blend the best of traditional CRO services with strategic resourcing.In today's conversation, we'll explore how functional partnerships are evolving, how sponsors are rethinking outsourcing to meet modern challenges, and where the future of trial delivery is headed. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

As AI-generated content continues to flood the B2B landscape, many brands are asking an important question: How do we hold onto our purpose, and make sure the people we serve truly understand it?In this episode, Donna Peterson sits down with Abe Wang from Collaborative Drug Discovery (CDD) to explore how a highly technical, scientific company stays deeply purpose-driven while growing, innovating, and communicating authentically. From internal culture and humanitarian initiatives to writing a book as a marketing strategy, this conversation offers valuable insights for any B2B leader navigating growth without losing meaning.What You'll Learn in This Episode:How to clearly communicate your company's purpose to people outside your industryWhy internal marketing is just as important as external brand messagingHow purpose-driven culture helps teams stay engaged as companies scaleWays to reach new audiences while keeping communication personal and humanWhy CDD chose to write a book instead of relying on AI-generated contentHow original storytelling helps B2B brands stand out in crowded marketsEpisode Timestamps:00:00 – Holding onto voice and purpose in an AI-driven world02:06 – Introducing Abe Wang and Collaborative Drug Discovery04:41 – Explaining CDD's mission in simple, relatable terms08:21 – Internal marketing and keeping employees connected to purpose12:11 – Human stories behind CDD's work and humanitarian initiatives15:31 – Reaching new audiences through trust and personal connection17:46 – Why writing a book helped CDD differentiate its brand voice20:11 – Turning original stories into long-term marketing assetsFeatured Resource:Inside the CDD Vault: A Different Kind of Collaborative Drug Discovery➡️ Book Cover & Amazon Link: https://www.amazon.com/Inside-CDD-Vault-Different-Collaborative-ebook/dp/B0G2HR4WYJ/This book brings together personal stories from over two dozen CDD employees and collaborators, offering a rare look into how purpose, humanity, and scientific innovation intersect inside a growing B2B organization.About Collaborative Drug Discovery (CDD):Collaborative Drug Discovery (CDD) is on a mission to advance science through better data. CDD's flagship product, CDD Vault®, is a hosted informatics solution that allows researchers to organize data and experiments in context while securely collaborating in real time. For drug discovery teams using AI-based approaches, CDD Vault serves as a central repository for clean, reusable data that can be analyzed repeatedly across different algorithms, parameters, targets, or compounds. The platform also includes a RESTful API to support automated workflows and offers PharmaKB™, a Pharmaceutical KnowledgeBase providing semantic data on preclinical, clinical, and post-approval drug development. Learn more at www.collaborativedrug.comAbout Abe Wang:Abe Wang is the Head of Marketing at Collaborative Drug Discovery, where he leads strategic initiatives to elevate the CDD Vault brand and drive global engagement within the life sciences community. Since joining CDD in 2019, Abe has played a key role in expanding brand awareness and digital marketing efforts, supporting the company's growth as a leading SaaS informatics platform for scientific data management. Abe brings more than a decade of experience at the intersection of science and marketing. Prior to CDD, he held marketing leadership roles at Thermo Fisher Scientific and Affymetrix, focusing on market development, demand generation, and product strategy for life science technologies. Earlier in his career, Abe spent over seven years at SRI International, contributing to preclinical drug development and translational research. *** Reach out to dpeterson@worldinnovators.comif you'd like help building a marketing strategy that builds relationships and/or AI training for individuals or full teams. *** Visit www.worldinnovators.comfor more resources on building stronger marketing and leadership strategies. *** Subscribe to the B2B Marketing Excellence & AI Podcast for weekly insights into marketing, leadership, and the future of AI.

In this conversation, we pull back the curtain on alpha-gal syndrome diagnostic testing at Thermo Fisher Scientific with Gary Falcetano, PA-C. Gary shares insights into how the alpha-gal syndrome test works and answers some of our most frequently asked questions. How do you talk to your provider about being tested? Is the test covered by insurance? What provider can order the test? He also dives into how Allergy Insider, Thermo Fisher's patient resource, is bringing alpha-gal into the conversation. Tune in now to learn more! Gary Falcetano, PA-C, serves as Senior Manager Global Medical and Scientific Affairs for allergy at Thermo Fisher Scientific. Gary has been a Board Certified Physician Assistant for over 28 years, and is the host of Allergy Insider's ImmunoCAST podcast.Visit Allergy Insider to learn more about their patient resources and be sure to follow on social media: @allergyinsider

Dr. Anil Kane, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, joins Ross Katz to discuss how AI, machine learning, and digital tools are reshaping drug development. From predictive modeling for formulation to digital manufacturing efficiencies, discover how data-driven approaches are reducing time, cost, and complexity in pharma innovation. What You'll Learn in This Episode: >> How predictive modeling eliminates trial-and-error in drug formulation >> The role of AI/ML in improving manufacturing efficiency and reducing downtime >> How Thermo Fisher's ASAP program accelerates stability testing >> The future of digital transformation in pharma, including OpenAI partnerships >> Where human expertise fits in a digitally enhanced development pipeline Meet Our Guest Dr. Anil Kane is the Executive Director and Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, where he oversees a global team supporting drug development, scale-up, and technical strategy across sites in North America and Europe.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Anil Kane on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this episode of Data in Biotech, host Ross Katz sits down with John Liberty, Senior Bioanalysis Technical Sales Consultant at Thermo Fisher Scientific. They dive deep into how Watson LIMS™ supports regulated bioanalysis workflows, the evolving role of lab automation, and how Connect Enterprise aims to unify biotech digital ecosystems. What you'll learn in this episode: >> Why Watson LIMS is purpose-built for bioanalysis and how it enhances compliance and data traceability. >> The role of lab automation in boosting productivity and reducing manual tasks. >> How Connect Enterprise integrates lab systems across vendors into a seamless workflow.  >> Key considerations for implementing LIMS in startup versus established biotech environments. >> The ROI of digital lab solutions in supporting scalable, compliant biotech operations. Meet Our Guests John Liberty is a GMP-trained scientist with a strong focus on ELISA method development, validation, and transfer. He pairs his hands-on scientific background with experience in project management, CRO coordination, data analysis, and training, making him someone who really understands how work moves from the lab bench to real-world application. John has also spent time on the product and customer side, doing technical sales and demos for Watson LIMS™ software, giving him a rare blend of technical depth and communication skills. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with John Liberty  on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

In this Mol Bio Minutes episode, Thermo Fisher Scientific's Monika Jazdauskaitė dives into the versatile world of Recombinase Polymerase Amplification (RPA). Unlike PCR, RPA operates at a constant, low temperature (around 37–42°C), enabling fast, equipment-light workflows that are ideal for field diagnostics and decentralized labs. Monika explains how the method works and why RPA is emerging as a go-to technique for both DNA and RNA target detection.She highlights RPA's specificity, sensitivity, and robustness against common inhibitors like ethanol and heparin, critical for applications like respiratory pathogen detection or low-quality sample inputs. Plus, she shares how RPA's gentle conditions and lyophilization compatibility make it a strong candidate for stabilizing next-generation sequencing (NGS) libraries, especially those with high GC content.Whether you're looking to simplify pathogen detection or streamline your sequencing prep, RPA offers a compelling alternative to traditional amplification. And with ready-to-use kits like the Invitrogen™ Lyo-ready RPA Kit, Thermo Fisher is helping researchers bring speed and stability to molecular workflows, all with no thermal cycler required. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher Scientific, identifies the significant challenges in the US organ transplant system that must be addressed to meet the demand for organs.  Patient access to transplant care is hindered by geography, the need to match donors and recipients, and the threat of organ rejection. Living donations, particularly of kidneys and livers, are a solution to address the organ shortage, as organs from living donors often lead to better outcomes and can be scheduled to avoid damage caused by organ transportation. Tina explains, "So first of all, I would say that organ transplantation saves thousands of lives a year and gives patients with end-stage organ disease the ability to extend their lives meaningfully for many years. However, the organ transplant system in the US is not perfect, and it faces several real challenges. The most pressing challenge is a persistent imbalance between organ supply and demand, in that far more patients are in need of a lifesaving transplant than there are available organs, which leaves many patients waiting too long for a compatible organ or perhaps will never receive a compatible match. And unfortunately, for those patients left waiting, many get sicker, and often patients die while waiting on the wait list. So this gap in supply and demand is real, and it underscores the importance of living donation, which can help expand the pool of available organs and give patients a chance at the timely care that they need." "Another significant challenge is patient access to organ transplant care. For instance, in the weeks leading up to the transplant procedure and after the procedure, patients are often required to be living or situated near the hospital or the transplant center where the surgery is performed. This can pose a challenge to those who simply don't reside in areas where there are major transplant centers or who can't afford temporary housing. And that creates a socioeconomic inequity when it comes to access." #ThermoFisherScientific #Transplantation #OrganDonors #LivingDonation #HeartTransplant #OrganTransplants thermofisher.com Download the transcript here

Tina Liedtky, President of Transplant Diagnostics at Thermo Fisher Scientific, identifies the significant challenges in the US organ transplant system that must be addressed to meet the demand for organs.  Patient access to transplant care is hindered by geography, the need to match donors and recipients, and the threat of organ rejection. Living donations, particularly of kidneys and livers, are a solution to address the organ shortage, as organs from living donors often lead to better outcomes and can be scheduled to avoid damage caused by organ transportation. Tina explains, "So first of all, I would say that organ transplantation saves thousands of lives a year and gives patients with end-stage organ disease the ability to extend their lives meaningfully for many years. However, the organ transplant system in the US is not perfect, and it faces several real challenges. The most pressing challenge is a persistent imbalance between organ supply and demand, in that far more patients are in need of a lifesaving transplant than there are available organs, which leaves many patients waiting too long for a compatible organ or perhaps will never receive a compatible match. And unfortunately, for those patients left waiting, many get sicker, and often patients die while waiting on the wait list. So this gap in supply and demand is real, and it underscores the importance of living donation, which can help expand the pool of available organs and give patients a chance at the timely care that they need." "Another significant challenge is patient access to organ transplant care. For instance, in the weeks leading up to the transplant procedure and after the procedure, patients are often required to be living or situated near the hospital or the transplant center where the surgery is performed. This can pose a challenge to those who simply don't reside in areas where there are major transplant centers or who can't afford temporary housing. And that creates a socioeconomic inequity when it comes to access." #ThermoFisherScientific #Transplantation #OrganDonors #LivingDonation #HeartTransplant #OrganTransplants thermofisher.com  Listen to the podcast here

In this Mol Bio Minutes episode, Thermo Fisher Scientific's Dr. Agnė Alminaitė unveils an exciting new approach for assay developers: Dry-Ready™ reagents for RT-LAMP and RT-qPCR. These innovations eliminate the need for lyophilizers by enabling air drying of molecular assays in a standard heating oven, producing room temperature-stable assays in under two hours.Agnė walks listeners through how Dry-Ready differs from traditional Lyo-Ready™ and lyophilization methods, while delivering similar stability and performance. She explains the critical role of thermostable enzymes and specially developed excipient mixes that protect enzyme function during the drying process.The episode introduces two new kits: the Dry-Ready™ RT-LAMP Kit, ideal for flexible assay development and point-of-care settings, and the one-step Dry-Ready™ RT-qPCR Kit, a powerful tool for simplified, dual-function reactions. Both kits are customizable and empower even small labs to stabilize assays without complex equipment.Whether you're commercializing a kit or looking to simplify your workflow, this episode offers actionable insight into next-generation assay stabilization. And don't miss the special promo code below!Helpful resource links mentioned in this episode:Learn more about air-drying and lyophilization for assay stabilization.Visit the product pages for the Dry-Ready products Agnė introduced:Invitrogen Dry-Ready™ RT-qPCR KitInvitrogen Dry-Ready™ RT-LAMP KitAccess all Thermo Fisher Scientific promotional offersAccess your exclusive Speaking of Mol Bio promotional offerEnter code “CAZDUA” if in the U.S.Enter code “CZ7F19” in in Canada Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Beau Wangtrakuldee is the founder and CEO of AmorSui, a science-backed medical supply brand bringing innovation, safety, and sustainability to the $58B PPE industry. A former scientist turned entrepreneur, Beau is reimagining protective apparel with clean chemistry, circular materials, and design that finally puts the user first.After a lab accident exposed the flaws in traditional PPE, Beau built AmorSui to bridge the gap between safety, comfort, and sustainability: offering PFAS-free, recyclable, and biobased alternatives trusted by global brands like Thermo Fisher Scientific and Benco Dental.Whether you're building a mission-driven ecommerce brand or rethinking your product's lifecycle, Beau shares a masterclass in turning real-world problems into scalable innovation, proving that circular design and commercial growth can coexist.In This Conversation We Discuss:[00:30] Intro[01:01] Building comfort and safety into every product[01:46] Creating a business from personal experience[04:37] Designing products people actually reuse[06:10] Validating ideas through real user stories[08:12] Raising capital before manufacturing begins[08:47] Allocating funds beyond first production run[09:45] Navigating minimum order quantity realities[10:32] Launching pre-sales with finished prototypes[11:04] Stay updated with new episodes[11:14] Balancing safety standards with speed to market[12:37] Episode Sponsors: Electric Eye & Heatmap[15:18] Marketing through word-of-mouth momentum[17:01] Refining targeting through early experiments[19:00] Discovering growth through customer feedback[21:34] Testing demand before building logistics[23:17] Learning quickly by shipping imperfect products[24:09] Focusing every decision on the end userResources:Subscribe to Honest Ecommerce on YoutubeModern PPE brand that protects people and the planet amorsui.com/Follow Beau Wangtrakuldee linkedin.com/in/beauwangtrakuldeeSchedule an intro call with one of our experts electriceye.io/connectClear, real-time data built for ecommerce optimization heatmap.com/honestIf you're enjoying the show, we'd love it if you left Honest Ecommerce a review on Apple Podcasts. It makes a huge impact on the success of the podcast, and we love reading every one of your reviews!

In this Mol Bio Minutes episode, Dr. Will Barnes, a plant biologist turned senior sales training specialist at Thermo Fisher Scientific, reflects on his time at the bench and the molecular lessons learned along the way. Will dives deep into the difficulties of RNA work in plant systems—carbohydrate contamination, genomic DNA carryover, secondary structure—and how these hindered everything from cloning and expression analysis to sequencing and qPCR.Through real-world anecdotes, he explains how high-quality reagents and systems helped him troubleshoot and resolve recurring issues, ultimately saving time and improving data reliability. He advocates for prioritizing upstream steps like RNA integrity and reverse transcription fidelity instead of chasing fixes at the end of the workflow.Listeners will leave with a deeper appreciation for the critical role of sample prep in molecular biology workflows and why investing in better tools pays off in cleaner data, greater confidence, and fewer headaches. Will's experience is a relatable reminder that smarter choices lead to better science.Helpful resource links mentioned in this episode:Learn about molecular cloning workflows and Gateway cloning solutionsExplore a variety of resources on reverse transcriptionTaqMan vs SYBR Chemistry for Real-Time PCRUsing MagMAX kits for automated nucleic acid extractionLearn more about, or order,SuperScript IV VILO Master MixExplore RNA/DNA quantification solutions, including Qubit and Nanodrop instruments----------------------------------------------------------------------------------------------Limited time promotional offer – Be one of the first 75 listeners to spend $500 and get 40% off all eligible reverse transcriptase, plastics, enzymes, and cloning reagents. Visit thermofisher.com/sombpromo for full detailsEnter promo code CAZDUA in the U.S.A.Enter promo code CZ7F19 in Canada Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

On episode 139 of PSQH: The Podcast, Gary Falcetano, Manager of Scientific Affairs – Allergy and Autoimmune Disease at Thermo Fisher Scientific, discusses what caregivers should know about Pollen Food Allergy Syndrome.

Welcome to the Olink® Proteomics in Proximity podcast!  Below are some useful resources mentioned in this episode:  Olink tools and software·       Olink® Explore HT, Olink's most advanced solution for high-throughput biomarker discovery, measuring 5400+ proteins simultaneously with a streamlined workflow and industry-leading specificity: https://olink.com/products-services/exploreht/  UK Biobank Pharma Proteomics Project (UKB-PPP), one of the world's largest scientific studies of blood protein biomarkers conducted to date, https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news/uk-biobank-launches-one-of-the-largest-scientific-studies  World Health Organization (2003). Adherence to long-term therapies: evidence for action (PDF). Geneva: World Health Organisation. ISBN 978-92-4-154599-0 Research articles and news·       Thermo Fisher Scientific's Olink Platform Selected for World's Largest Human Proteome Studyhttps://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientifics-Olink-Platform-Selected-for-Worlds-Largest-Human-Proteome-Study/default.aspx·       Hamilton Se-Hwee Oh et al 2025. Plasma proteomics links brain and immune system aging with healthspan and longevityhttps://www.nature.com/articles/s41591-025-03798-1. Nature Medicine (2025)·       Song, Y., Abuduaini, B., Yang, X. et al. Identification of inflammatory protein biomarkers for predicting the different subtype of adult with tuberculosis: an Olink proteomic study. Inflamm. Res. 74, 60 (2025). https://doi.org/10.1007/s00011-025-02020-9·       Ferhan Qureshi et al 2023. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Proteomics clinical application 2023·       Dhindsa, R.S., Burren, O.S., Sun, B.B. et al. Rare variant associations with plasma protein levels in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06547-xhttps://www.nature.com/articles/s41586-023-06547-x·       Sun, B.B., Chiou, J., Traylor, M. et al.  Plasma proteomic associations with genetics and health in the UK Biobank. 2023 Nature, DOI: 10.1038/s41586-023-06592-6 https://www.nature.com/articles/s41586-023-06592-6 https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehac495/6676779·       Eldjarn GH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023 Oct;622(7982):348-358. doi: 10.1038/s41586-023-06563-xhttps://www.nature.com/articles/s41586-023-06563-x#Sec44·        Carrasco-Zanini et al 2024 Proteomic prediction of common and rare diseases. https://www.nature.com/articles/s41591-024-03142-z . NatureMedicine volume 30,  pages2489–2498 (2024)·       Watanabe K, Wilmanski T, Diener C, et al. Multiomic signatures of body mass index identify heterogeneous health phenotypes and responses to a lifestyle intervention.https://www.nature.com/articles/s41591-023-02248-0·       Petrera A, von Toerne C, Behlr J, et al. Multiplatform Approach for Plasma Proteomics: Complementarity of Olink Proximity Extension Assay Technology to Mass Spectrometry-Based Protein Profiling. (2020) Journal of Proteome Research, https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.0c00641·       Multicenter Collaborative Study to Optimize Mass Spectrometry Workflows of Clinical Specimens. Kardell O, von Toerne C, Merl-Pham J, König AC, Blindert M, Barth TK, Mergner J, Ludwig C, Tüshaus J, Eckert S, Müller SA, Breimann S, Giesbertz P, Bernhardt AM, Schweizer L, Albrecht V, Teupser D, Imhof A, Kuster B, Lichtenthaler SF, Mann M, Cox J, Hauck SM. J Proteome Res. 2024 Jan 5;23(1):117-129. doi: 10.1021/acs.jproteome.3c00473. Epub 2023 Nov 28. PMID: 38015820 https://pubs.acs.org/doi/10.1021/acs.jproteome.3c00473·       Wei, S., Shen, R., Lu, X. et al. Integrative multi-omics investigation of sleep apnea: gut microbiome metabolomics, proteomics and phenome-wide association study. Nutr Metab (Lond) 22, 57 (2025). https://doi.org/10.1186/s12986-025-00925-0·       Liu, L., Li, M., Qin, Y. et al. Childhood obesity and insulin resistance is correlated with gut microbiome serum protein: an integrated metagenomic and proteomic analysis. Sci Rep 15, 21436 (2025). https://doi.org/10.1038/s41598-025-07357-z·       Zhang, Xiaotao et al.Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. eBioMedicine, Volume 98, 104873 (2023.).  10.1016/j.ebiom.2023.104873·      &nb...

Did you know that IgE, the antibody responsible for allergic reactions, is 30,000 times less abundant than other immunoglobulins in the body? This staggering fact underscores the importance of highly sensitive allergy diagnostics. In this episode, we pull back the curtain on what happens to allergy diagnostic blood samples after they leave your clinic. Clinical laboratory expert Jessica Murphy, MLS (ASCP), guides us through the intricate process of specific IgE testing, from sample processing to result interpretation. Learn about the advanced technology behind ImmunoCAP™ allergy diagnostics, the role of Phadia™ Laboratory Systems in ensuring accurate results, and the meticulous quality control measures employed by Thermo Fisher Scientific. Discover how regional respiratory profiles are curated, the significance of binding capacity in IgE detection, and the collaborative effort between clinicians and lab experts in reaching accurate diagnoses. Gain insights into interpreting allergy diagnostic results and their impact on patient management, illustrated through a real-world case study of a young patient with respiratory symptoms. Resources and references here: https://www.thermofisher.com/phadia/us/en/resources/immunocast/allergy-diagnostics-blood-draw-process.html

US President Trump announced trade deals with the Philippines, Indonesia and Japan, with the latter involving a USD 550bln investment in the US and 15% tariffs for Japanese goods.US stocks closed mixed with underperformance in tech, APAC stocks were mostly higher; Nikkei 225 outperformed.Japanese PM Ishiba is likely to announce resignation as early as this month, according to Yomiuri. Other reports suggest August-end. European equity futures indicate a positive cash market open with Euro Stoxx 50 future up 1.2% after the cash market closed with losses of 1.0% on Tuesday.DXY is flat, havens (CHF, JPY) lag G10 peers, antipodeans lead, EUR/USD remains on a 1.17 handle.Looking ahead, highlights include EU Consumer Confidence, US Existing Home Sales, Supply from UK, Germany & US.Earnings from VAT, Lonza, Equinor, Thales, Tesla, Alphabet, ServiceNow, IBM, Chipotle, GE Vernova, Freeport, AT&T, Thermo Fisher Scientific, Lamb Weston, Infosys, Moody's, CME & Hilton.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

US President Trump announced trade deals with the Philippines, Indonesia and Japan, with the latter involving a USD 550bln investment in the US and 15% tariffs for Japanese goods.Japanese PM Ishiba is likely to announce resignation as early as this month, according to Yomiuri – reports which he later pushed back on.European bourses benefit from the US-Japan trade deal; RTY continues to outperform.USD is flat, Antipodeans are the G10 outperformers whilst the EUR lags a touch; JPY choppy on US-Japan trade deal and reports surrounding PM Ishiba.JGBs slump on trade updates, peers elsewhere lower given the risk tone and into supply.Crude complex choppy awaiting fresh catalysts, XAU takes a breather following recent upside.Looking ahead, US Existing Home Sales, Supply from the US. Earnings from Tesla, Alphabet, ServiceNow, IBM, Chipotle, GE Vernova, Freeport, AT&T, Thermo Fisher Scientific, Lamb Weston, Infosys, Moody's, CME & Hilton.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Imagine a future where diseases like leukemia, sickle cell anemia and multiple sclerosis are no longer life sentences, but treatable and even curable. That is the promise of gene therapy.In this episode, Namritha Ravinder, director of cell biology at Thermo Fisher Scientific, explains the groundbreaking technologies that correct the genetic errors in our cells that lead to disease. These gene therapies may offer permanent solutions with single-dose treatments. Namritha also provides an expert's view on what's to come from more than 2,000 gene therapies in the pipeline, and the innovation needed to make these new treatments accessible to patients.

In today's episode, supported by Thermo Fisher Scientific, we had the pleasure of speaking with Apar Kishor Ganti, MD; and Allison Cushman-Vokoun, MD, PhD, FCAP, about the FDA approval of the Oncomine DX Express Test for use as a companion diagnostic for sunvozertinib (Zegfrovy) in EGFR exon 20 insertion mutation–positive non–small cell lung cancer and for use in tumor profiling. Dr Ganti is a professor in the University of Nebraska Medical Center (UNMC) Division of Oncology & Hematology, the Dr. and Mrs. D. Leon UMNC Research Fund Chair in Internal Medicine, and the associate director for Clinical Research at the Fred & Pamela Buffett Cancer Center in Omaha. Dr Cushman is the Henry F. Krous Professor of Pathology, a professor in the UNMC Department of Pathology, Microbiology and Immunology, director of the Division of Diagnostic Molecular Pathology and Human Genetics, medical director of the Molecular Diagnostics and Personalized Medicine Laboratory at Nebraska Medicine, director of the Molecular Genetic Pathology Fellowship Program, and associate director of the UMNC MD-PhD Scholars Program.  In our exclusive interview, Drs Ganti and Cushman discussed the significance of the launch of the Oncomine DX Express Test, the benefits and limitations of rapid next-generation sequencing, and features that set Oncomine DX apart from other available tests. 

In this expansive episode, sound healer and former corporate scientist, Ruslana Remennikova, joins me to discuss her incredible new book, "Activating Our 12-Stranded DNA."  This episode is loaded with info about our 12-stranded DND – the concept that suggests humans possess a potential for a much more complex DNA structure with 12 strands.A truly fascinating topic. Some of the concepts include how:- How to transform our DNA from the standard double helix into its 12-stranded, dodecahedral form.- How this form encompasses sound frequency, water consciousness, generational trauma, and the transformative ability to unlock profound spiritual potential, heightened consciousness, and psychic abilities.An absolutely incredible episode! Listen or watch now. About: Ruslana Remennikova is a former research scientist for the Fortune 100 – ranked company Thermo Fisher Scientific where she worked with vaccine sciences. In a 2016 leap of faith for a more meaningful life, she left the world of corporate science to open a sound medicine practice later while writing her first book. She is the founder of Songbird Science, a research and education enrichment provider exploring frequency and consciousness. Born in Ukraine, she currently resides in central Virginia. https://ruslanaremennikova.comIf you liked this episode, please write a review and follow me on Instagram. Thank you so much for listening.Thank you to my new sponsors. This Episode is brought to you by: • The Sattva Collection - 10% off with code TheConsciousDiva• Birds & Beans Organic Coffee - 10% off with DIVA2025The Conscious Diva Podcast wouldn't be possible without your support! A massive THANK YOU for listening. If you'd like to further support my podcast, you can: • SUBSCRIBE in your favorite podcast player or YouTube. • FOLLOW me @The_Conscious_Diva on Instagram.  • BOOK a session with Tatyanna. • SIGN-UP to receive emails at www.tatyannawright.com

988: In this episode of Technovation, we feature a panel from the Metis Strategy Summit moderated by Metis Strategy's Co-Head of Executive Networks, Media, and Research Steven Norton, exploring how senior technology executives are aligning AI to their business strategy. Joining the conversation are Ryan Snyder, CIO of Thermo Fisher Scientific; Ramkumar Rayapureddy, CIO of Viatris; and Allen Fazio, CIO of Houlihan Lokey. Together, they share how their organizations are evolving from isolated AI pilots to holistic strategies grounded in business value, robust governance, and relentless data modernization. The panelists discuss the practical realities of establishing clear measurement frameworks, navigating the tension between centralized control and decentralized innovation, and leading cultural change as AI adoption accelerates across regulated and fast-moving industries.

US equity futures are sharply lower, as risk sentiment deteriorated amid escalating Middle East tensions. Asian markets fell broadly, European equities are also trading lower. Israel launched airstrikes on Iranian nuclear and military targets, prompting fears of regional escalation. President Trump said the US was not involved but convened his cabinet; Israel declared a state of emergency and signaled operations may continue for days. Trump reiterated unilateral tariff threats and raised the prospect of 25% auto tariffs. Trade talks with Japan, India, and the EU remain challenging ahead of the G7 summit. US inflation data showed further cooling; jobless claims steady but continuing claims rose to a multi-year high.Companies Mentioned: NVIDIA, Thermo Fisher Scientific, CK Hutchison Holdings, COSCO SHIPPING Holdings, Blackrock

Our guest this week is Rick Bolle of Naperville, IL founding pastor of the newly formed Front Porch Church, father of two and retired businessman. Rick and his wife, Alinda, have been married for 32 years and are the proud parents of two adult children.  Shortly after retiring from Thermo Fisher Scientific in 2022, where he was a Senior Safety Specialist, Rick felt a calling to start or plant Front Porch Church.   Established in 2023, Front Porch Church helps people of all ability find their way back to God.  FPC is specifically designed to welcome individuals with special needs and their families.  Weekly services offer a worship experience that embraces all expressions and all movements, ensuring that everyone feels included, valued, safe and loved.It's an illuminating conversation and we'll hear it on this episode of the SFN Dad to Dad Podcast.Show LinksPhone – (630) 442-4031Email – rickbolle2@icloud.comLinkedIn –  https://www.linkedin.com/in/rick-bolle-6955b150/Website - https://kidsmatter2us.org/front-porch-church/Facebook – https://www.facebook.com/groups/962219779455651Special Fathers Network -SFN is a dad to dad mentoring program for fathers raising children with special needs. Many of the 800+ SFN Mentor Fathers, who are raising kids with special needs, have said: "I wish there was something like this when we first received our child's diagnosis. I felt so isolated.  There was no one within my family, at work, at church or within my friend group who understood or could relate to what I was going through."SFN Mentor Fathers share their experiences with younger dads closer to the beginning of their journey raising a child with the same or similar special needs. The SFN Mentor Fathers do NOT offer legal or medical advice, that is what lawyers and doctors do. They simply share their experiences and how they have made the most of challenging situations.Check out the 21CD YouTube Channel with dozens of videos on topics relevant to dads raising children with special needs - https://www.youtube.com/channel/UCzDFCvQimWNEb158ll6Q4cA/videosPlease support the SFN. Click here to donate: https://21stcenturydads.org/donate/Special Fathers Network: https://21stcenturydads.org/  SFN Mastermind Group - https://21stcenturydads.org/sfn-mastermind-group/

Laboratories use up to ten times the energy of typical office spaces, making sustainability in science a pressing issue. In this episode of Science with a Twist, host Terri Somers speaks with James Connelly, CEO of My Green Lab, and Alyssa Caddle, Senior Director of Global Sustainability at Thermo Fisher Scientific, about steps laboratories can take to reduce their environmental impact. From energy-efficient cold storage to sustainable lab products, James and Alyssa discuss how the life science industry is evolving to meet ambitious climate goals. 

In this episode of Technovation, host Peter High speaks with Ryan Snyder, Senior VP & CIO of Thermo Fisher Scientific, a $40 billion global leader in life sciences. Ryan shares how AI, automation, and data strategy are driving digital transformation—optimizing operations, accelerating clinical trials, and enhancing customer experiences.